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efforts to prevent breeding in plants is suggested for pre-
vention of dengue in the district.
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Introduction: There is growing political and ﬁnancial
commitment to eradicate malaria, and hence integrated
control approaches, including biological larviciding, deserve
attention. The purpose of this study was to investigate
whether repeated application of Bacillus thuringiensis (Bti)
and B. sphaericus (Bs) have an effect on malaria transmis-
sion.
Material and methods: Larvae collection surveys con-
ducted during 9 months showed the effectiveness of Bti and
Bs. After the 8th treatment, Anopheles larvae were absent
from the breeding sites. Culex larvae decreased after the
3rd treatment. Adult mosquitoes were captured by 56 man-
nights in 2006 (February, May, August, and November), inside
and outside households during two consecutive days.
Results: From a total of 2361 mosquitoes captured,
59.5% belonged to Anopheles genus. An. funestus s.l. was
the most abundant, accounting for 82% of total Anophe-
lines caught, followed by An. gambiae s.l. (17.2%). Peak
abundance was observed during the rainy seasons, while,
lowest biting rates were observed during the dry seasons.
The comparison of entomological transmission parameters
recorded, with data from 2005, showed that larvicide treat-
ments permitted a signiﬁcant decrease of An. funestus
(5.1 bites/person/night; P < 0.001) and An. gambiae (18.7
bites/person/night; P < 0.001) biting rates. The infestation
rate was stable for both species, with a much higher rate
observed for An. gambiae (15.1%) when compared to An.
funestus (2.1%). The annual entomological inoculation rate
(EIR) for An. gambiae (281 infective bites/person/night;
P = 0.088) was similar in 2005 and 2006, while the annual
EIR of An. funestus (142 infectives bites/person/night;
P = 0.005) has been drastically reduced.
Discussion and conclusion: The routine application of lar-
vicides in mosquitoes breading sites decreased the number
of breeding sites containing Anopheles and Culex larvae,
which could have favoured the signiﬁcant reduction of
An. funestus and An. gambiae biting rates, and a drastic
decrease of An. funestus EIR.
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Background: Triomune is standard of care for HIV in
Uganda. We aimed to determine the steady-state PK,
bioequivalence and tolerability of generic and branded for-
mulations of 3TC, d4T, and NVP in HIV-infected Ugandans.
Methods: This randomized, open label, cross-over study
included HIV-patients on Triomune 40® (3TC 150mg, d4T
40mg, NVP 200mg) for at least 1 month. On day 1, patients
were randomized to generic or branded formulation. After
at least 28 days, 3TC, d4T and NVP plasma PK was assessed
over 12 h. The day after, the alternate formulation was
administered and 28 days later drug PK was re-assessed.
Plasma PK was determined by a fully validated method using
HPLC-UV detection. Bioequivalence was achieved if the 90%
conﬁdence intervals (CI) for the geometric mean ratio (GMR)
of generic/branded for maximum plasma concentration
(Cmax) and the area under the concentration-time curve
(AUC) was within 0.8—1.25 (US Food and Drug Administration
bioequivalence criteria). Questionnaires were administered
to assess the tolerability of the 2 formulations.
Results: 16 (10 females) patients completed the study.
Median (IQR) age, weight, CD4 count were 37y (33.7—40),
65 kg (63.4—66), 292c/ul (220.7—344.5). All were on daily
cotrimoxazole. The GMR (90%CI) for 3TC, d4T, and NVP were
1.11 (0.95—1.30),0.92 (0.78—1.08), and 0.84 (0.64—1.11)
for Cmax; and 1.06 (0.94—1.20),0.83 (0.70—0.97), and 0.88
(0.71—1.10) for AUC. d4T plasma concentrations were sig-
niﬁcantly lower for the generic formulation (18% decrease).
3TC, d4T, and NVP PK parameter interindividual variabil-
ity ranged from 28% to 99%. There were no differences in
tolerability for the 2 formulations.
Conclusions: Although the strict deﬁnition of bioequiv-
alence was not met, drug exposures were similar for the
2 formulations, with the exception of d4T. However, the
clinical signiﬁcance of this remains unclear.
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